Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $16.4 million.

  • Iradimed's Total Liabilities rose 5137.42% to $16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year increase of 5137.42%. This contributed to the annual value of $11.5 million for FY2024, which is 4450.69% down from last year.
  • Latest data reveals that Iradimed reported Total Liabilities of $16.4 million as of Q3 2025, which was up 5137.42% from $12.1 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Total Liabilities ranged from a high of $20.7 million in Q4 2023 and a low of $9.1 million during Q1 2021
  • For the 5-year period, Iradimed's Total Liabilities averaged around $11.8 million, with its median value being $11.3 million (2023).
  • In the last 5 years, Iradimed's Total Liabilities surged by 7512.33% in 2023 and then crashed by 4450.69% in 2024.
  • Over the past 5 years, Iradimed's Total Liabilities (Quarter) stood at $10.7 million in 2021, then grew by 10.58% to $11.8 million in 2022, then surged by 75.12% to $20.7 million in 2023, then crashed by 44.51% to $11.5 million in 2024, then soared by 42.26% to $16.4 million in 2025.
  • Its Total Liabilities stands at $16.4 million for Q3 2025, versus $12.1 million for Q2 2025 and $11.7 million for Q1 2025.